Gilead Sciences | GILD - Ebitda





Ebitda Veränderung Datum
AbbVie USD 3.69B 1.68B 2026-03
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
ALKERMES USD 139.22M 58.96M 2026-06
Alnylam Pharmaceuticals USD 245.34M 59.15M 2026-06
Amgen USD 3.86B 1.28B 2026-03
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 4.24B 1.37B 2026-03
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 10.29B 1.86B 2026-03
Gilead Sciences USD 3.51B 489M 2026-03
GlaxoSmithKline GBP 3.51B 734M 2026-06
Glaxosmithkline GBP 2.77B 1.98B 2026-03
Incyte USD 778.57M 410.6M 2026-06
J&J USD 8.27B 1.08B 2026-03
Merck USD -1.54B 7.84B 2026-03
Moderna USD -1.26B 468M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 6.48B 1.19B 2026-06
Pfizer USD 6.01B 18M 2026-06
PTC Therapeutics USD 61.98M 132.97M 2026-03
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Sanofi EUR 3.69B 375M 2026-06
Sarepta Therapeutics USD 375.48M 627.68M 2026-03
United Therapeutics USD 355M 11.1M 2026-06
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06